Incidence of hypertension and proteinuria in patients treated with bevacizumab versus bevacizumab biosimilar

83 Background: Biosimilar products are proven to have no clinically meaningful differences in terms of safety and effectiveness with the reference product, however, to our knowledge, there is limit...